Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic
© 2020 Wiley Periodicals LLC..
The safety of immunosuppressive treatment in patients with Immune-Mediated Inflammatory Diseases (IMIDs) during the Coronavirus pandemic is questioned and it is utmost important for public health. We searched studies trough MEDLINE/EMBASE database, including patient with IMID, undergoing immunosuppressive treatment with a positive diagnosis for SARS-CoV 2. We included 11 studies for the descriptive analysis and 10 studies for the pooled analysis, with a total population of 57 and 53 IMID-affected SARS-CoV-positive patients respectively. Overall no death was reported; 16 patients were hospitalized (30.2%) and only two cases were admitted to Intensive Care Unit (ICU) (3.8%). We found a significant association between the risk of hospitalization and older age (P .03), obesity (P .02), and presence of multi-comorbidity (P .03). No significant association was found between the risk of hospitalization and the use of biological or conventional DMARDs (respectively P .32 and .26), neither when they are used combined (P .85). We found consistent results in the sub-analysis of Psoriasis: 10 patients were hospitalized (31.3%) and only one case was admitted to Intensive Care Unit (ICU) (3.1%) Particular attention should be placed for patients with older age, obesity and multi-comorbidity that are at higher risk of hospitalization.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Dermatologic therapy - 33(2020), 6 vom: 15. Nov., Seite e14204 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Giuliani, Federica [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antirheumatic Agents |
---|
Anmerkungen: |
Date Completed 13.01.2021 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/dth.14204 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314031464 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314031464 | ||
003 | DE-627 | ||
005 | 20231225151844.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/dth.14204 |2 doi | |
028 | 5 | 2 | |a pubmed24n1046.xml |
035 | |a (DE-627)NLM314031464 | ||
035 | |a (NLM)32829511 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Giuliani, Federica |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 13.01.2021 | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a The safety of immunosuppressive treatment in patients with Immune-Mediated Inflammatory Diseases (IMIDs) during the Coronavirus pandemic is questioned and it is utmost important for public health. We searched studies trough MEDLINE/EMBASE database, including patient with IMID, undergoing immunosuppressive treatment with a positive diagnosis for SARS-CoV 2. We included 11 studies for the descriptive analysis and 10 studies for the pooled analysis, with a total population of 57 and 53 IMID-affected SARS-CoV-positive patients respectively. Overall no death was reported; 16 patients were hospitalized (30.2%) and only two cases were admitted to Intensive Care Unit (ICU) (3.8%). We found a significant association between the risk of hospitalization and older age (P .03), obesity (P .02), and presence of multi-comorbidity (P .03). No significant association was found between the risk of hospitalization and the use of biological or conventional DMARDs (respectively P .32 and .26), neither when they are used combined (P .85). We found consistent results in the sub-analysis of Psoriasis: 10 patients were hospitalized (31.3%) and only one case was admitted to Intensive Care Unit (ICU) (3.1%) Particular attention should be placed for patients with older age, obesity and multi-comorbidity that are at higher risk of hospitalization | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a biologic | |
650 | 4 | |a coronavirus | |
650 | 4 | |a immune-mediate inflammatory disease | |
650 | 4 | |a immunosuppressive drugs | |
650 | 4 | |a psoriasis | |
650 | 7 | |a Antirheumatic Agents |2 NLM | |
650 | 7 | |a Biological Products |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
700 | 1 | |a Gualdi, Giulio |e verfasserin |4 aut | |
700 | 1 | |a Amerio, Paolo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 33(2020), 6 vom: 15. Nov., Seite e14204 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2020 |g number:6 |g day:15 |g month:11 |g pages:e14204 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.14204 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2020 |e 6 |b 15 |c 11 |h e14204 |